License

License Not Specified

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

Comparison of the Oxyntomodulin Analog LY2944876 to Once-Weekly Exenatide and to Placebo in Patients with Type 2 Diabetes

To demonstrate a dose-response relationship of once-weekly subcutaneous injections of LY2944876 on hemoglobin A1c HbA1c change from baseline and from this dose-response relationship at 12 weeks determine which LY2944876 doses are superior to placebo in patients with T2DM inadequately controlled with diet and exercise alone or treated with a stable dose of metformin

FieldValue
Modified
2020-05-25
Release Date
2020-05-25
Identifier
87673f2d-de10-4405-ac59-fec09f75dd04
License
License Not Specified
Public Access Level
Public